Post graduate Resident, Department of Oral & Maxillofacial Surgery, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Science, Saveetha University, Chennai India.
Professor, Department of Oral & Maxillofacial Surgery, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Science, Saveetha University, Chennai India.
J Oral Maxillofac Surg. 2022 Jan;80(1):63-69. doi: 10.1016/j.joms.2021.07.013. Epub 2021 Jul 19.
The aim of this study was to compare the clinical efficacy of injection of 2 long-acting amide local anesthetic agents - bupivacaine and ropivacaine with and without 4 mg dexamethasone in patients undergoing third molar extraction.
A prospective randomized double blind controlled trial was conducted among 68 patients with impacted mandibular third molars. Group A and B were the control groups and received 1.8 mL of 0.5% bupivacaine hydrochloride and 0.75% ropivacaine hydrochloride, respectively. Group A1 and B1 were experimental groups and received modified twin mixes which were 1.8 mL of 0.5% bupivacaine hydrochloride + 1mL/4mg dexamethasone and 0.75% ropivacaine hydrochloride + 1 mL/4mg dexamethasone, respectively. Visual analog pain scale, mouth opening measurement and facial swelling were assessed at the time of injection and postoperative days 1, 3, and 7.
The mean visual analogue scale score for pain on local anesthesia injection was found to be less in both experimental groups- Group A1 (2.94) and B1 (2.41) as compared to control groups- Group A (3.59) and B (3.06). The durations of soft tissue anesthesia were higher as compared to their respective controls for both Group A1 and B1. Patients in both control groups A and B had an increased postoperative swelling, pain and trismus.
Intraoperative and postoperative comfort in both the experimental groups were higher than those for control groups, thereby establishing the clinical efficacy of both modified twin mixes for use in surgical extraction of mandibular third molars.
本研究旨在比较两种长效酰胺局部麻醉剂——布比卡因和罗哌卡因分别与和不与 4 毫克地塞米松联合注射用于下颌第三磨牙拔除患者的临床疗效。
一项前瞻性随机双盲对照试验在 68 名下颌阻生第三磨牙患者中进行。A 组和 B 组为对照组,分别接受 1.8 毫升 0.5%盐酸布比卡因和 0.75%罗哌卡因。A1 组和 B1 组为实验组,分别接受改良双混合液,即 1.8 毫升 0.5%盐酸布比卡因+1 毫升/4 毫克地塞米松和 0.75%罗哌卡因+1 毫升/4 毫克地塞米松。在注射时以及术后第 1、3 和 7 天评估视觉模拟疼痛量表、张口度和面部肿胀。
在注射局部麻醉时,两组实验组——A1 组(2.94)和 B1 组(2.41)的平均视觉模拟评分均低于对照组——A 组(3.59)和 B 组(3.06)。两组实验组 A1 组和 B1 组的软组织麻醉持续时间均长于各自的对照组。两组对照组 A 组和 B 组的患者在术后均出现肿胀、疼痛和张口受限增加。
两组实验组在术中及术后舒适度均高于对照组,从而证实改良双混合液在下颌第三磨牙手术拔除中的临床疗效。